232 related articles for article (PubMed ID: 24991185)
1. The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dismutase-1 (Sod1)-knockout mice.
Kojima T; Dogru M; Ibrahim OM; Nagata T; Higa K; Shimizu T; Shirasawa T; Satake Y; Shimazaki S; Shimazaki J; Tsubota K
Mol Vis; 2014; 20():929-38. PubMed ID: 24991185
[TBL] [Abstract][Full Text] [Related]
2. The effects of 3% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice.
Ikeda K; Simsek C; Kojima T; Higa K; Kawashima M; Dogru M; Shimizu T; Tsubota K; Shimazaki J
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):739-750. PubMed ID: 29484560
[TBL] [Abstract][Full Text] [Related]
3. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice.
Ohguchi T; Kojima T; Ibrahim OM; Nagata T; Shimizu T; Shirasawa T; Kawakita T; Satake Y; Tsubota K; Shimazaki J; Ishida S
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7793-802. PubMed ID: 24168989
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Short-Term Effects of Diquafosol and Rebamipide on Mucin 5AC Level on the Rabbit Ocular Surface.
Hori Y; Kageyama T; Sakamoto A; Shiba T; Nakamura M; Maeno T
J Ocul Pharmacol Ther; 2017; 33(6):493-497. PubMed ID: 28346860
[TBL] [Abstract][Full Text] [Related]
5. Age-Related Conjunctival P2Y2 Receptor Alterations in the Cu, Zn-Superoxide Dismutase-1 (Sod1)-Knockout Dry Eye Model Mice.
Dogru M; Shinzawa M; Kojima T; Shimizu T; Tsubota K
Eye Contact Lens; 2019 Nov; 45(6):405-409. PubMed ID: 30908311
[TBL] [Abstract][Full Text] [Related]
6. The Role of 2% Rebamipide Eye Drops Related to Conjunctival Differentiation in Superoxide Dismutase-1 (Sod1) Knockout Mice.
Kojima T; Simsek C; Igarashi A; Aoki K; Higa K; Shimizu T; Dogru M; Tsubota K; Shimazaki J
Invest Ophthalmol Vis Sci; 2018 Mar; 59(3):1675-1681. PubMed ID: 29625494
[TBL] [Abstract][Full Text] [Related]
7. Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models.
Choi KE; Song JS; Kang B; Eom Y; Kim HM
Curr Eye Res; 2017 May; 42(5):666-671. PubMed ID: 27791390
[TBL] [Abstract][Full Text] [Related]
8. Effects of eye drops containing a mixture of 3% diquafosol sodium and tocopherol acetate (vitamin E) on the ocular surface of murine dry eye.
Li L; Jin R; Li Y; Yoon HS; Yoon HJ; Yoon KC
Cutan Ocul Toxicol; 2021 Dec; 40(4):350-358. PubMed ID: 34496685
[TBL] [Abstract][Full Text] [Related]
9. The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 (
Yagi-Yaguchi Y; Kojima T; Higa K; Dogru M; Ibrahim OM; Shimizu T; Tsubota K; Shimazaki J
Diagnostics (Basel); 2020 Jan; 10(1):. PubMed ID: 31906291
[TBL] [Abstract][Full Text] [Related]
10. Changes in Tear Volume after 3% Diquafosol Treatment in Patients with Dry Eye Syndrome: An Anterior Segment Spectral-domain Optical Coherence Tomography Study.
Lee KB; Koh KM; Kwon YA; Song SW; Kim BY; Chung JL
Korean J Ophthalmol; 2017 Aug; 31(4):306-312. PubMed ID: 28752695
[TBL] [Abstract][Full Text] [Related]
11. Conjunctival expression of the P2Y2 receptor and the effects of 3% diquafosol ophthalmic solution in dogs.
Terakado K; Yogo T; Kohara Y; Soeta S; Nezu Y; Harada Y; Hara Y; Amasaki H; Tagawa M
Vet J; 2014 Oct; 202(1):48-52. PubMed ID: 25178686
[TBL] [Abstract][Full Text] [Related]
12. Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition.
Shigeyasu C; Yamada M; Akune Y; Tsubota K
Jpn J Ophthalmol; 2015 Nov; 59(6):415-20. PubMed ID: 26310103
[TBL] [Abstract][Full Text] [Related]
13. Effects of Diquafosol Ophthalmic Solution on Quality of Life in Dry Eye Assessed Using the Dry Eye-Related Quality-of-Life Score Questionnaire: Effectiveness in Patients While Reading and Using Visual Display Terminals.
Utsunomiya T; Kawahara A; Hanada K; Yoshida A
Cornea; 2017 Aug; 36(8):908-914. PubMed ID: 28542084
[TBL] [Abstract][Full Text] [Related]
14. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye.
Shimazaki-Den S; Iseda H; Dogru M; Shimazaki J
Cornea; 2013 Aug; 32(8):1120-5. PubMed ID: 23635860
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials.
Wu D; Chen WQ; Li R; Wang Y
Cornea; 2015 Jun; 34(6):644-50. PubMed ID: 25909234
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients.
Takamura E; Tsubota K; Watanabe H; Ohashi Y;
Br J Ophthalmol; 2012 Oct; 96(10):1310-5. PubMed ID: 22914501
[TBL] [Abstract][Full Text] [Related]
17. Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
Park DH; Chung JK; Seo DR; Lee SJ
Am J Ophthalmol; 2016 Mar; 163():122-131.e2. PubMed ID: 26685791
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease.
Mun Y; Kwon JW; Oh JY
BMC Ophthalmol; 2018 Sep; 18(1):237. PubMed ID: 30185156
[TBL] [Abstract][Full Text] [Related]
19. Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
Hwang HS; Sung YM; Lee WS; Kim EC
Cornea; 2014 Sep; 33(9):935-41. PubMed ID: 25055152
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
